PE-backed biotech company sets price range for IPO
March 22, 2021
Olink, the developer of a protein biomarker platform, has set the price range for its upcoming IPO at between $16 and $18 per share, according to a regulatory filing. The Swedish company is planning to offer 17.6 million American depositary shares in the US-based listing. Olink was acquired by Summa Equity in 2019. The company reported revenue of $54 million last year.